content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 26, 2005
                                                          ------------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       000-14879              22-2322400
  ------------------------------   --------------------------  -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
             of Incorporation)                                 Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  -----------------------------------------------------------      ---------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  
  Item 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT OF PRINCIPAL OFFICERS.
  
       On September 26, 2005, Cytogen  Corporation (the "Company")  announced that
  Thomas S. Lytle has decided to retire from his position as Senior Vice President
  of Sales and Marketing of the Company effective October 31, 2005.
  
       The full text of the September 26, 2005 press release  issued in connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  
  Item 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
          Exhibit No.                          Description
          -----------                          -----------
  
             99.1         Press Release of Cytogen Corporation dated September 26,
                          2005.
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
  
                                              CYTOGEN CORPORATION
  
  
  
                                              By:    /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   September 26, 2005
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
          Exhibit No.                          Description
          -----------                          -----------
  
             99.1         Press Release of Cytogen Corporation dated September 26,
                          2005.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_092605-lytle.txt", "description": "FORM 8-K FILED 9/26/05 - LYTLE PRESS RELEASE", "secsgml_size_bytes": 4102}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "051102577"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 26, 2005
                                                          ------------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       000-14879              22-2322400
  ------------------------------   --------------------------  -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
             of Incorporation)                                 Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  -----------------------------------------------------------      ---------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  Item 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT OF PRINCIPAL OFFICERS.
  
       On September 26, 2005, Cytogen  Corporation (the "Company")  announced that
  Thomas S. Lytle has decided to retire from his position as Senior Vice President
  of Sales and Marketing of the Company effective October 31, 2005.
  
       The full text of the September 26, 2005 press release  issued in connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  Item 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
          Exhibit No.                          Description
          -----------                          -----------
  
             99.1         Press Release of Cytogen Corporation dated September 26,
                          2005.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                              CYTOGEN CORPORATION
  
                                              By:    /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   September 26, 2005
  EXHIBIT INDEX
  
          Exhibit No.                          Description
          -----------                          -----------
  
             99.1         Press Release of Cytogen Corporation dated September 26,
                          2005.